A review of therapies for advanced cancers licenced by the EMA between 2009 and 2013 concluded that for more than half of these drugs there was little evidence of overall survival or quality of life benefit. | Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor EGFR and anaplastic lymphoma kinase ALK negative advanced or metastatic non-small cell lung cancer A systematic review and secondary analysis of trials
